|
Case
|
Treatment
|
Response to treatment
|
Overall survival duration (months)
|
Relapse
|
Outcome
|
Cause of death
|
|---|
|
1
|
R-CHOP ×5
|
PR
|
45.0
|
No
|
Dead
|
Cholangiocarcinoma
|
|
(75% dose)
|
|
2
|
R-CHOP ×6
|
PR
|
7.9
|
No
|
Dead
|
Pneumonia
|
|
IT*
|
|
3
|
R-CHOP ×2
|
NA
|
4.0
|
−
|
Dead
|
Exacerbation of pulmonary fibrosis
|
|
(70% dose)
|
|
4
|
R-MPV ×4
|
CR
|
40.1
|
No
|
Alive
|
−
|
|
IT*
|
|
HD-Ara-C ×2
|
|
WBRT
|
|
5
|
R-CHOP ×6
|
CR
|
28.0
|
No
|
Alive
|
−
|
|
HD-MTX ×2
|
|
IT*
|
|
6
|
R-CHOP ×8
|
CR
|
24.8
|
No
|
Alive
|
−
|
|
IT*
|
|
7
|
R-COP ×1
|
NA
|
2.6
|
−
|
Dead
|
Pneumonia
|
|
(60% dose)
|
- *IT represents prophylactic administration of methotrexate and/or cytarabine.
-
CR complete response, CRu unconfirmed complete response, HD-Ara-C high-dose cytarabine, HD-MTX high-dose methotrexate, IT intrathecal themotherapy, NA not assessable, R-CHOP rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone, R-COP rituximab, cyclophosphamide, vincristine, and prednisolone, R-MPV rituximab, high-dose methotrexate, procarbazine, and vincristine, WBRT Whole-brain radiotherapy.
